NEW YORK, Nov. 7, 2017 /PRNewswire/ -- Pomerantz LLP is
investigating claims on behalf of investors of Alkermes plc ("Alkermes" or the "Company") (NASDAQ: ALKS). Such
investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Alkermes and certain of its officers and/or directors have engaged in securities fraud or
other unlawful business practices.
[Click
here to join a class action]
On November 6, 2017, U.S. Senator Kamala Harris announced that
she is opening an investigation into Alkermes's sales practices for its opioid-addiction treatment Vivitrol. Senator Harris
specifically stated that the Company "aggressively marketed" its medication, convincing judges and prison officials to use it
rather than more proven addiction-treatment products, and spent hundreds of thousands of dollars lobbying policymakers.
On this news, Alkermes's share price fell $2.23, or 4.37%, to close at $48.76 on November 6, 2017.
The Pomerantz Firm, with offices in New York, Chicago,
Los Angeles, and Paris, is acknowledged as one of the premier
firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham
L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class
actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights
of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-alkermes-plc--alks-300551063.html
SOURCE Pomerantz LLP